[A19-15] Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57
Last updated 22.03.2019
Commission awarded on 12.03.2019 by the Federal Joint Committee (G-BA).
Adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy
Added benefit still not proven for both research questions after analysis of further data
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-57||Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.